Efficacy of progesterone vaginal suppositories in alleviation of nervous symptoms in patients with premenstrual syndrome

Elizabeth R. Baker, Robert G. Best, Rocco L. Manfredi, Laurence Demers, Gordon C. Wolf

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Purpose: To further investigate the efficacy of progesterone in the treatment of the symptoms of premenstrual syndrome (PMS). Materials and Methods: From an initial cohort of 25 subjects diagnosed with moderate to severe PMS, 17 reproductive age females completed the 7-month, doubleblind, placebo controlled trial using 200-mg vaginal progestone suppositories. Multiple modalities for evaluating symptoms were employed, including the Spielberger self-evaluation rating, the Beck depression inventory, and the Hamilton anxiety scale. In addition, each subject was interviewed by a psychiatrist on a monthly basis; ovulation was determined monthly using a basal body temperature chart; serum hormonal assays included beta endorphin, progesterone, follicle stimulating hormone, luteinizing hormone, estradiol, and prolactin. Results: Hormonal assays confirmed no differences between treatment and control groups. Overall scores on all test vehicles were likewise not significantly different between the two groups; however, in the subcategory of nervous symptoms, a significant improvement was found in symptoms relating to tension, mood swings, irritability, anxiety and lack of control. Conclusions: Metabolites of progesterone (pregnanolone and allopregnanolone) may play a physiologic role as anxiolytic agents, perhaps modifying mood and anxiety; the current study confirms the utility of twice daily, 200-mg progesterone vaginal suppositories, in the alleviation of some PMS symptoms relating to anxiety and irritability. Further evaluation may be warranted to ascertain which patients in the known heterogeneous PMS population may be most likely to benefit from such treatment.

Original languageEnglish (US)
Pages (from-to)205-209
Number of pages5
JournalJournal of Assisted Reproduction and Genetics
Volume12
Issue number3
DOIs
StatePublished - Mar 1 1995

Fingerprint

Premenstrual Syndrome
Suppositories
Progesterone
Anxiety
Pregnanolone
Diagnostic Self Evaluation
beta-Endorphin
Anti-Anxiety Agents
Follicle Stimulating Hormone
Luteinizing Hormone
Ovulation
Body Temperature
Prolactin
Psychiatry
Estradiol
Therapeutics
Placebos
Depression
Equipment and Supplies
Control Groups

All Science Journal Classification (ASJC) codes

  • Reproductive Medicine
  • Genetics
  • Obstetrics and Gynecology
  • Developmental Biology
  • Genetics(clinical)

Cite this

Baker, Elizabeth R. ; Best, Robert G. ; Manfredi, Rocco L. ; Demers, Laurence ; Wolf, Gordon C. / Efficacy of progesterone vaginal suppositories in alleviation of nervous symptoms in patients with premenstrual syndrome. In: Journal of Assisted Reproduction and Genetics. 1995 ; Vol. 12, No. 3. pp. 205-209.
@article{e69ade59c1ad49b2b3e8d80aef49b458,
title = "Efficacy of progesterone vaginal suppositories in alleviation of nervous symptoms in patients with premenstrual syndrome",
abstract = "Purpose: To further investigate the efficacy of progesterone in the treatment of the symptoms of premenstrual syndrome (PMS). Materials and Methods: From an initial cohort of 25 subjects diagnosed with moderate to severe PMS, 17 reproductive age females completed the 7-month, doubleblind, placebo controlled trial using 200-mg vaginal progestone suppositories. Multiple modalities for evaluating symptoms were employed, including the Spielberger self-evaluation rating, the Beck depression inventory, and the Hamilton anxiety scale. In addition, each subject was interviewed by a psychiatrist on a monthly basis; ovulation was determined monthly using a basal body temperature chart; serum hormonal assays included beta endorphin, progesterone, follicle stimulating hormone, luteinizing hormone, estradiol, and prolactin. Results: Hormonal assays confirmed no differences between treatment and control groups. Overall scores on all test vehicles were likewise not significantly different between the two groups; however, in the subcategory of nervous symptoms, a significant improvement was found in symptoms relating to tension, mood swings, irritability, anxiety and lack of control. Conclusions: Metabolites of progesterone (pregnanolone and allopregnanolone) may play a physiologic role as anxiolytic agents, perhaps modifying mood and anxiety; the current study confirms the utility of twice daily, 200-mg progesterone vaginal suppositories, in the alleviation of some PMS symptoms relating to anxiety and irritability. Further evaluation may be warranted to ascertain which patients in the known heterogeneous PMS population may be most likely to benefit from such treatment.",
author = "Baker, {Elizabeth R.} and Best, {Robert G.} and Manfredi, {Rocco L.} and Laurence Demers and Wolf, {Gordon C.}",
year = "1995",
month = "3",
day = "1",
doi = "10.1007/BF02211800",
language = "English (US)",
volume = "12",
pages = "205--209",
journal = "Journal of Assisted Reproduction and Genetics",
issn = "1058-0468",
publisher = "Springer New York",
number = "3",

}

Efficacy of progesterone vaginal suppositories in alleviation of nervous symptoms in patients with premenstrual syndrome. / Baker, Elizabeth R.; Best, Robert G.; Manfredi, Rocco L.; Demers, Laurence; Wolf, Gordon C.

In: Journal of Assisted Reproduction and Genetics, Vol. 12, No. 3, 01.03.1995, p. 205-209.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy of progesterone vaginal suppositories in alleviation of nervous symptoms in patients with premenstrual syndrome

AU - Baker, Elizabeth R.

AU - Best, Robert G.

AU - Manfredi, Rocco L.

AU - Demers, Laurence

AU - Wolf, Gordon C.

PY - 1995/3/1

Y1 - 1995/3/1

N2 - Purpose: To further investigate the efficacy of progesterone in the treatment of the symptoms of premenstrual syndrome (PMS). Materials and Methods: From an initial cohort of 25 subjects diagnosed with moderate to severe PMS, 17 reproductive age females completed the 7-month, doubleblind, placebo controlled trial using 200-mg vaginal progestone suppositories. Multiple modalities for evaluating symptoms were employed, including the Spielberger self-evaluation rating, the Beck depression inventory, and the Hamilton anxiety scale. In addition, each subject was interviewed by a psychiatrist on a monthly basis; ovulation was determined monthly using a basal body temperature chart; serum hormonal assays included beta endorphin, progesterone, follicle stimulating hormone, luteinizing hormone, estradiol, and prolactin. Results: Hormonal assays confirmed no differences between treatment and control groups. Overall scores on all test vehicles were likewise not significantly different between the two groups; however, in the subcategory of nervous symptoms, a significant improvement was found in symptoms relating to tension, mood swings, irritability, anxiety and lack of control. Conclusions: Metabolites of progesterone (pregnanolone and allopregnanolone) may play a physiologic role as anxiolytic agents, perhaps modifying mood and anxiety; the current study confirms the utility of twice daily, 200-mg progesterone vaginal suppositories, in the alleviation of some PMS symptoms relating to anxiety and irritability. Further evaluation may be warranted to ascertain which patients in the known heterogeneous PMS population may be most likely to benefit from such treatment.

AB - Purpose: To further investigate the efficacy of progesterone in the treatment of the symptoms of premenstrual syndrome (PMS). Materials and Methods: From an initial cohort of 25 subjects diagnosed with moderate to severe PMS, 17 reproductive age females completed the 7-month, doubleblind, placebo controlled trial using 200-mg vaginal progestone suppositories. Multiple modalities for evaluating symptoms were employed, including the Spielberger self-evaluation rating, the Beck depression inventory, and the Hamilton anxiety scale. In addition, each subject was interviewed by a psychiatrist on a monthly basis; ovulation was determined monthly using a basal body temperature chart; serum hormonal assays included beta endorphin, progesterone, follicle stimulating hormone, luteinizing hormone, estradiol, and prolactin. Results: Hormonal assays confirmed no differences between treatment and control groups. Overall scores on all test vehicles were likewise not significantly different between the two groups; however, in the subcategory of nervous symptoms, a significant improvement was found in symptoms relating to tension, mood swings, irritability, anxiety and lack of control. Conclusions: Metabolites of progesterone (pregnanolone and allopregnanolone) may play a physiologic role as anxiolytic agents, perhaps modifying mood and anxiety; the current study confirms the utility of twice daily, 200-mg progesterone vaginal suppositories, in the alleviation of some PMS symptoms relating to anxiety and irritability. Further evaluation may be warranted to ascertain which patients in the known heterogeneous PMS population may be most likely to benefit from such treatment.

UR - http://www.scopus.com/inward/record.url?scp=0029009147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029009147&partnerID=8YFLogxK

U2 - 10.1007/BF02211800

DO - 10.1007/BF02211800

M3 - Article

C2 - 8520187

AN - SCOPUS:0029009147

VL - 12

SP - 205

EP - 209

JO - Journal of Assisted Reproduction and Genetics

JF - Journal of Assisted Reproduction and Genetics

SN - 1058-0468

IS - 3

ER -